Goldman Sachs Leads the Charge
The Series C round was spearheaded by Growth Equity at Goldman Sachs Alternatives, with robust backing from returning investors such as Vertex Ventures Israel, Grove Ventures, and Alive. This investment underscores a resounding vote of confidence in Navina’s vision of harnessing AI to dismantle data silos and revolutionize patient care.
“This investment is a powerful validation of Navina’s vision to improve patient outcomes and healthcare economics by breaking down data barriers with AI,” said Ronen Lavi, Navina’s co-founder and CEO. “Goldman Sachs’ market leadership will be instrumental as we enter this pivotal growth phase. With this capital, we will accelerate AI innovation and make every patient interaction more empathetic, personalized, and proactive.”
Expanding Across the U.S. Healthcare Market
The fresh capital injection will also turbocharge Navina’s expansion across the U.S., allowing it to integrate AI-driven intelligence into every outpatient interaction. With artificial intelligence rapidly redefining healthcare, Navina is poised to lead the charge.
“Navina stands at the forefront of AI-driven transformation in healthcare,” said Irit Kahan, managing director in Growth Equity at Goldman Sachs Alternatives. “Their deep integration into clinical workflows and unmatched provider trust position them to drive meaningful impact across the healthcare ecosystem. We believe their AI-powered platform is a game-changer.”
